The Artificial Intelligence for Early Drug Discovery conference brings together a diverse group of experts from chemistry, target discovery, pharmacology, and bioinformatics, to talk about the increasing use of computational tools, artificial intelligence (AI) models, machine learning (ML) algorithms, and data mining in preclinical drug development. The talks will highlight how AI/ML can help in drug design, target identification, lead optimization, PK/PD predictions, and early safety assessments. There will be discussions on the caveats and limitations of AI/ML-driven decision-making using relevant case studies and research findings.